Larimar Therapeutics (LRMR) Stock Forecast: StockMap's 2-Week Call

LRMR stock forecast: StockMap's model makes no two-week call on Larimar Therapeutics after the Nov 13 close: its evidence is split, 5 reasons for and 10 against. Right in 2 of 3 two-week windows on LRMR since Sep 24; by chance, a call on the same dates was right 51% of the time.

Larimar Therapeutics last closed at $3.02, +11.85% on the session.

Against the IVW growth benchmark the position is +12.76% over the forecast window.

Larimar Therapeutics' market cap is $313.72M as of November 13, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -13 (too close to call).

Where LRMR sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

22 daily calls for LRMR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Larimar Therapeutics in the 8th percentile on return on equity, where 100 is best.

Larimar Therapeutics is classified under Health Care / Biotechnology.

StockMap tracks Larimar Therapeutics as the 204th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.

On that composite Larimar Therapeutics ranks 133rd of 391 in the group, against a group median of -0.24.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 13, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Larimar Therapeutics (LRMR) — StockMap 2-week forecast & tracked accuracy